<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02441972</url>
  </required_header>
  <id_info>
    <org_study_id>LS2011051</org_study_id>
    <nct_id>NCT02441972</nct_id>
  </id_info>
  <brief_title>Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics</brief_title>
  <official_title>Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuxi No. 4 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuxi No. 4 People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 18F-Al labeled RGD is safety and effective
      for cancer diagnosis and therapy response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observe radiation dose to healthy volunteers and patients; the correlation between integrin
      level and tumor/metastases uptake.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety data included vital signs (blood pressure, respiratory rate, heart rate, and body temperature) (composite)</measure>
    <time_frame>1 day</time_frame>
    <description>Safety data were collected before and after injection of 18F-Al-NOTA-PRGD2. physical examination; ECG; laboratory parameters (blood routine, liver function and kidney function) and adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>radioactive distribution of normal organ, standard uptake value of tumor</measure>
    <time_frame>60 minutes</time_frame>
    <description>Visual analysis whole body 18F-Al-NOTA-PRGD2 PET;Regions of interest (ROIs) were drawn manually on each image with the assistance of corresponding CT images. The results were expressed as standardized uptake value (SUV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance analysis to assess &quot;sensitivity,specificity,accuracy,etc&quot;</measure>
    <time_frame>1 day-1 year</time_frame>
    <description>compare the Diagnostic outcome to pathology or clinic follow-up,then to gather statistics of sensitivity,specificity,accuracy,etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tumors</condition>
  <condition>Carcinoma, Bronchogenic</condition>
  <condition>Breast Carcinoma</condition>
  <condition>Cancer of Head and Neck</condition>
  <condition>Lymphoma, Malignant</condition>
  <condition>Soft Tissue Neoplasms</condition>
  <arm_group>
    <arm_group_label>18F-Al-NOTA-PRGD2 PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imaging with 18F-Al-NOTA-PRGD2 PET/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-Al-NOTA-PRGD2 PET/CT</intervention_name>
    <description>18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.</description>
    <arm_group_label>18F-Al-NOTA-PRGD2 PET/CT</arm_group_label>
    <other_name>18F-Alfatide II PET/CT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteers or patients with age more than 18 yeas;

          2. The patients have been diagnosed with cancer or suspected with cancer;

          3. It must fulfill the ethical requirements and subjects have signed an informed consent.

        Exclusion Criteria:

          1. Pregnancy or nursing mothers;

          2. Having drugs or alcohol dependence;

          3. Hypersensitive to the active or inactive ingredients of the study drug;

          4. Having attended other drug clinical trials within three months;

          5. Cardiac functional insufficiency;

          6. Hepatic and renal function insufficiency;

          7. Hypertensive patients with serious complications;

          8. Endangering the safety of life.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weixing Wan, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Wuxi No. 4 People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjing Yu, Dr.</last_name>
    <phone>86-15312238622</phone>
    <email>ycj_wxd1978@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wuxi No. 4 People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunjing Yu, M.D.</last_name>
      <phone>15312238622</phone>
      <email>ycj_wxd1978@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006 Jul 1;12(13):3942-9.</citation>
    <PMID>16818691</PMID>
  </results_reference>
  <results_reference>
    <citation>Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, Lordick F, Schwaiger M. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008 Jan;49(1):22-9. Epub 2007 Dec 12.</citation>
    <PMID>18077538</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Soft Tissue Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

